WO1998024817A1 - Nouvel adn, nouvelle proteine et nouvel anticorps - Google Patents
Nouvel adn, nouvelle proteine et nouvel anticorps Download PDFInfo
- Publication number
- WO1998024817A1 WO1998024817A1 PCT/JP1997/004470 JP9704470W WO9824817A1 WO 1998024817 A1 WO1998024817 A1 WO 1998024817A1 JP 9704470 W JP9704470 W JP 9704470W WO 9824817 A1 WO9824817 A1 WO 9824817A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- dna
- cell
- cells
- protein according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a protein having an ability to activate eosinophils, a DNA or an oligonucleotide encoding the protein, a recombinant vector containing the DNA, a transformant containing the recombinant vector, A method for producing a protein using the transformant, a cell that specifically acts on the protein, a cell membrane or receptor that specifically binds to the protein, an agonist or antagonist of the protein, The present invention relates to antibodies that bind and therapeutic or diagnostic methods for allergic inflammation, eosinophilic pneumonia, idiopathic eosinophilia, autoimmune diseases, malignant tumors or parasitic infections using the same. Background art
- Vascular endothelial cells are cells that make up the innermost part of blood vessels and can come into direct contact with blood cells. In the case of inflammation, the force of leukocytes to adhere and accumulate on the blood vessel wall and infiltrate the tissue over time. Endothelial cells play a major role in causing leukocyte adhesion by expressing the adhesion molecule ⁇ chemokine. I have. In addition, it has been reported that the expression of chemokines, adhesion molecules of vascular endothelial cells, is promoted or suppressed by cytokines secreted by leukocytes.
- ⁇ ⁇ F- ⁇ tumor necros is factor ⁇
- E-selectin an adhesion molecule
- IL-8 interleukin-1 8
- cytokines are involved in inflammation, including interleukin-14 (IL-4), which is secreted from activated T cells and mast cells.
- IL-4 was first reported as a B cell growth / differentiation factor, but subsequent studies have reported that it exerts a versatile effect on various cells, especially in the blood cell system.
- IL— 4 From the observation of knockout mice, the effect in vivo was to differentiate T cells into type 2 T-cells and to convert cytokines from type 2 helper T cells to IL-4, IL-5, IL-6, etc.
- IL- 4 is One involved deeply in the infiltration of the eosinophilic Has been reported. For example, when cancer cells that express IL-4 were transplanted into mice, eosinophils and macrophages accumulated in the transplanted area and the cancer cells died [Cel, 57, 503 (1989)].
- eosinophils and mast cells accumulated in the eyelid of IL-4 expressing transgenic mice and caused allergic inflammation [Cell, 62, 457 (1990)], and expressed lung-specifically
- eosinophils and mast cells accumulated in the lungs and showed asthma-like symptoms such as epithelial cell thickening [Proc. Natl. Acad. Sc, 93, 7821 (1996)
- monkeys receiving continuous subcutaneous administration of IL-14 reported inflammation of blood vessels associated with eosinophil infiltration [Toxicologic Payhology, 19, 251 (1991)] or IL-4 gene knockout.
- mice In mice, the number of eosinophils infiltrating due to allergic reactions due to antigen sensitization is low. There is a report that which was then [Nature, 362, 245 (1993)]. Therefore, it is expected that among molecules whose expression is induced by IL_4 in vascular endothelial cells, there are molecules related to allergic inflammatory diseases and eosinophil infiltration. We believe that adhesion molecules involved in eosinophil adhesion to endothelial cells and chemokines involved in eosinophil activation and migration play an important role in eosinophil infiltration into allergic inflammatory sites.
- VCAM-1 vascular cell adhesion molecule-1
- L-selectin ligand L-selectin ligand
- P-selectin P-selectin
- Chemokines are molecules that have the activity of causing leukocytes to migrate toward higher chemokine concentrations via receptors, and play an important role in leukocyte infiltration. It is also known that binding of chemokines to receptors increases intracellular calcium concentration. In addition, chemokines not only have a chemotactic activity but also have the effect of activating white blood cells.For example, they have been reported to cause the activation of the adhesion molecule integrin and the promotion of degranulation and proliferation of white blood cells. [Nature, 361, 79 (1993), Journal of Leukocyte Biology, 59, 81 (1996)].
- chemokines are not only used for inflammation as described above, but also for leukocytes such as atherosclerosis where foamed macrophages accumulate in the vascular smooth muscle layer through vascular endothelial cells, and autoimmune diseases where activated lymphocytes attack themselves. It is thought to be a molecule that is deeply involved in diseases that are thought to be involved in the activation and migration of the disease. In addition, some chemokines have the effect of inhibiting proliferation of hematopoietic stem cells [Nature, 344, 442 (1990)].
- CXCR4 chemokine receptor 4
- CC chemokines act on monocytes among leukocytes
- CXC chemokines act on neutrophils in many cases.However, the types of chemokines that act on them and the intensity of their effects differ depending on the type of chemokine. Regulation of chemokine gene expression is also different for each chemokine. Thus, the secretion of chemodynamic proteins may depend on cells and tissues or the stimuli they receive.
- Eotaxin eotaxin
- RANTES RANTES
- MCP-3 MCP-4
- eotaxin-2 have been reported as chemokines that act on eosinophils.
- eotaxin has an eosinophil-specific action
- antigen Attention has been paid to the increased expression in animal allergy models due to sensitization.
- eotaxin gene knockout mice eotaxin is normally involved in maintaining the number of peripheral eosinophils, and eotaxin infiltration of pathological eosinophils during allergic inflammation was suggested to be involved only in the early stage, and that chemokines other than eotaxin were also involved in the early stage [J. Exp. Med., 185, 785 (1997)].
- chemokines can be used to activate activated eosinophils at sites of malignancy and parasite infection. If they can accumulate, these diseases can be treated It is thought that it can come. Disclosure of the invention
- the present invention relates to the following (1) to (35).
- a protein having an amino acid sequence represented by SEQ ID NO: 13, or an amino acid sequence in which one or more amino acids are deleted, substituted or added in the amino acid sequence, and capable of activating eosinophils (Hereinafter, also referred to as the protein of the present invention).
- DNA a DNA encoding the protein of (1), or a DNA that hybridizes with the DNA under stringent conditions and encodes a protein capable of activating eosinophils (hereinafter referred to as “DNA”); , Also referred to as the DNA of the present invention).
- a recombinant vector containing the DNA according to (2) (hereinafter, also referred to as the recombinant vector of the present invention).
- a transformant obtained by introducing the recombinant vector according to (3) into a host cell (hereinafter, also referred to as a transformant of the present invention).
- a method for producing a protein comprising culturing the transformant according to (4) in a medium, producing and accumulating the protein in a culture, and collecting the protein from the culture (hereinafter referred to as the present method). Also referred to as a method for producing the protein of the invention).
- a therapeutic agent for malignant tumor or parasitic infection comprising the protein according to (1).
- a method for treating a malignant tumor or a parasitic infection which comprises administering an effective amount of the protein according to (1).
- a method for detecting a cell on which the protein specifically acts, or a cell membrane or receptor specifically binding to the protein which comprises contacting the protein according to (1) with a test sample. .
- Corrected form (Rule 91) (10) Contacting the protein according to (1) with a test sample to obtain a cell on which the protein specifically acts, or a cell membrane or a receptor that specifically binds to the protein. Method.
- a method for diagnosing allergic inflammation, eosinophilic pneumonia, idiopathic eosinophilia or an autoimmune disease comprising using the antibody according to (14).
- a diagnostic agent for allergic inflammation, eosinophilic pneumonia, idiopathic eosinophilia or an autoimmune disease comprising the antibody according to (14).
- a therapeutic agent for allergic inflammation, eosinophilic pneumonia, idiopathic eosinophilia or autoimmune disease comprising the antibody according to (14).
- (21) A method for treating allergic inflammation, eosinophilic pneumonia, idiopathic eosinophilia or an autoimmune disease, comprising administering an effective amount of the antibody according to (14).
- (26) A method for detecting mRNA encoding the protein according to (1), comprising using the DNA according to (22) or (23) or the oligonucleotide according to (24) or (25). .
- a medicament comprising the DNA according to (23) or the oligonucleotide according to (25).
- a therapeutic agent for allergic inflammation, eosinophilic pneumonia, idiopathic eosinophilia or an autoimmune disease which comprises the DNA according to (23) or the oligonucleotide according to (25).
- a vector for gene therapy of a disease, a malignant tumor or a parasitic infection (hereinafter, also referred to as a gene therapy vector of the present invention).
- "having the ability to activate eosinophils” means that the ability to act on eosinophils to promote or enhance the intracellular calcium concentration, intracellular signal transduction system or cell response system. Means to have.
- the protein of the present invention may be a protein having the amino acid sequence represented by SEQ ID NO: 13 or one or more amino acids deleted in the amino acid sequence as long as the protein has an ability to activate eosinophils. It may be a protein consisting of a substituted or added amino acid sequence. Amino acid deletion, substitution or addition can be performed by the method described in Nucleic Acids Research, 10, 6487 (1982), Proc. Natl. Acad. Sci., USA, 79, 6409 (1982), Gene, 34, 315 ( 1985), Nucleic Acids Research, 13, 4431 (1985), Proc. Natl. Acad.Sci USA, 82, 488 (1985), and the like.
- the number of amino acids to be deleted, substituted or added is not particularly limited, it may be one to several tens, particularly one or several amino acids, and may be deleted, substituted or added by site-directed mutagenesis. Preferred above.
- the protein of the present invention in order for the protein of the present invention to have an ability to activate eosinophils, at least 60% or more, usually 80% or more, particularly 95% or more of the amino acid sequence described in SEQ ID NO: 13 It is preferred that they have homology.
- the protein of the present invention to be a chemokine protein, four Cys residues and their positions in the amino acid sequence shown in SEQ ID NO: 13 are substituted, inserted or deleted so as to be conserved. Protein is preferred.
- Examples of the DNA of the present invention include a DNA encoding the protein of the present invention, for example, a DNA having the nucleotide sequence of SEQ ID NO: 14 as a DNA encoding the protein having the amino acid sequence of SEQ ID NO: 13. .
- a DNA having the nucleotide sequence of SEQ ID NO: 14 as a DNA encoding the protein having the amino acid sequence of SEQ ID NO: 13.
- SEQ ID NO: 13 a DNA having the nucleotide sequence of SEQ ID NO: 14 as a DNA encoding the protein having the amino acid sequence of SEQ ID NO: 13.
- a DNA having a nucleotide sequence different from that of SEQ ID NO: 14 may encode a protein having the amino acid sequence shown in SEQ ID NO: 13.
- it is included in the DNA of the present invention.
- a DNA encoding the protein of the present invention and a DNA that hybridizes under stringent conditions are DNAs encoding the protein of the present invention, for example, a DNA having a base sequence represented by SEQ ID NO: 14. This refers to DNA obtained by using a colony hybridization method, a plaque hybridization method, a southern blot hybridization method, or the like.
- a hybridization solution having the following composition and containing a 32 P-labeled DNA having the nucleotide sequence of SEQ ID NO: 14 as a probe
- 6 XSSC [0.9 M NaCl, 90 mM sodium citrate; n XSSC: 1 Represents n-fold concentration of XSSC (150 mM NaCK 15 mM sodium citrate)]
- 5 X Denhardt's solution (0.1% Pseudoserum albumin, 0.1% phycoal, 0.1% polyvinylpyrrolidone), 0.5 % Sodium dodecyl sulfate (SDS), denatured DNA obtained by sonicating 20 g / ml salmon sperm DNA, heating in a boiling water bath for 5 minutes, and quenching in ice.
- the DNA of the present invention can be obtained by the following method.
- a cDNA fragment of the protein of the present invention can be obtained.
- the DNA of the present invention can be cloned by screening the vascular endothelial cell cDNA library using this cDNA fragment as a probe. The method for preparing the DNA of the present invention will be described below.
- eosinophils play an important role in allergic inflammatory diseases. Since IL_4 is deeply involved in the infiltration of eosinophils, blood vessels were obtained using the differential 'display method [Science, 257, 967 (1992), FEBS Letters, 351, 231 (1994)]. By analyzing genes whose mRNA expression levels fluctuate between when endothelial cells are stimulated with IL-4 and before, the DNAs involved in eosinophil infiltration are prepared. That is, total RNA is prepared from vascular endothelial cells stimulated with IL-4 and vascular endothelial cells not stimulated with IL-14.
- Methods for preparing total RNA include guanidine thiocyanate-cesium trifluoroacetate method [Methods in Enzymo 1 ogy, 154, 3 (1987)], guanidine acid thiocyanate 'phenol', and closed mouth form (AGPC) method [Analytical Biochemistry , 162, 156 (1987)].
- the cDNA fragment is amplified by polymerase chain reaction (hereinafter, referred to as PCR) using an anchor primer and an arbitrary primer for each of these cDNAs.
- Anchor primer is a primer in which an adenine, guanine or cytosine oligonucleotide excluding thymidine is added to the 3 'end of an oligo dT sequence associated with the 3' end poly A sequence of mRNA.
- the oligonucleotide having the nucleotide sequence shown in 4 can be mentioned.
- Optional primers are oligonucleotides that can amplify many types of cDNAs and can obtain a large number of amplified cDNA fragments in a single reaction.
- Operon Technologies 0PA-1 to 20; 0PB-1 to 20; 0PC-1 to 20;
- the optional primer preferably has a length of about 10 to 20 bases.
- the reaction mixture is electrophoresed with polyacrylamide gel, and the cDNA fragment in the gel is fluorescently stained with a DNA-specific fluorescent stain such as Cyber Green I.
- the amount of fluorescence of each fragment can be measured using a fluoroimager, and can be visualized as a light and shade band pattern.
- the fluorescence amount of the amplified fragment can be measured immediately after electrophoresis without fluorescent staining. Fluorescent labeling of the 5 'end of the primer can be carried out by a conventional method using fluorescein lithothioate.
- a portion of the excised gel is transformed into a ⁇ form to amplify the cDNA fragment in the gel by PCR, and the amplified fragment is used as it is, or after blunting the end with Pfu DNA polymerase, etc., and Integrate into vector and clone.
- Examples of the vector incorporating the amplified cDNA fragment include pT7Blue T-Vector [Novagen], pDIRECT [Clontech, Nucleic Acids Research 18, 6069 (1990)], pCR- Script Amp [manufactured by Stratagene], pCR2.1 [manufactured by Invitrogen], pCR-TRAP [manufactured by GenHunter], pTA (manufactured by Nitsubon Gene) and the like can be mentioned.
- the nucleotide sequence of the cloned cDNA fragment was determined by the didoxy method of Sanger et al. [Proc. Natl. Acad. ScI. USA, 74, 5463 (1977)] or Parkin- Determined using a DNA sequencer such as Elkin (Pharmacia) or Perkin Elmer.
- the novelty of the nucleotide sequence determined in this way can be determined by searching a nucleotide sequence database such as GenBank, EMBL and DDBJ using a homology search program such as BLAST. This can be confirmed by the absence of a nucleotide sequence having a clear homology that is considered to be identical.
- DNA having the novel nucleotide sequence obtained as described above examples include DNA having the nucleotide sequence of SEQ ID NO: 3.
- the DNA having the nucleotide sequence set forth in SEQ ID NO: 3 was obtained from a band in which the expression level was increased in vascular endothelial cells stimulated with IL-14 as compared to the case without stimulation with IL-4
- DNA was obtained by amplifying a part of cDNA encoding the HVC002 protein, which is a protein of the present invention, whose expression level increases in vascular endothelial cells stimulated with IL-14. It turns out to be something.
- the DNA of the invention can be obtained.
- MRNA is prepared as poly (A) + RNA from total RNA of vascular endothelial cells stimulated with IL-14 obtained by the above method.
- preparation method include a method using oligo (dT) cellulose [Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1989)] and the like.
- mRNA can be directly prepared from vascular endothelial cells stimulated with IL-14 using a kit such as Fast Track mRNA Isolation Kit [Invitrogen] or Quick Prep mRNA Purification Kit [Pharmacia]. This mRNA is converted into cDNA, integrated into an appropriate vector, and introduced into a host cell to prepare a cDNA library.
- a cloning vector for preparing a cDNA library any phage vector, plasmid vector, etc. can be used as long as it can replicate autonomously in E.
- coli K12 strain Specifically, ZAP Express [manufactured by Stratagene], pBluescript II SK (+) [Nucleic Acids Research, 17, 9494 (1989)], Lambda ZAP II (manufactured by Stratagene), gtlO, ⁇ gtll [DNA Cloning, A Practical Approach, II, 49 (1985)], A TriplEx (Clontech), AExCell (Pharmacia), pT7T318U (Pharmacia), pcD2 [Mol. Cell. Biol., 3, 280] (1983)].
- any microorganism that belongs to Escherichia coli can be used. Specifically, Escherichia coli XLl-Blue MRF '[Stratagene]. Escherichia coli C600 [Genetics, 39, 440 (1954)], Escherichia coli Y1088 [Science, 222, 778 (1983)], Escherichia coli Y1090 [Science, 222, 778 (1983)], Escherichia coli bandits 522 [J. Mol. Biol., 166, 1 (1983)], Escherichia coli K802 [J. Mol.
- Tightened paper (Rule 91) It can be used labeled with the 32 p or the like.
- the nucleotide sequence of the obtained cDNA can be determined using the above-described nucleotide sequence determination method.
- Examples of the DNA encoding the protein of the present invention obtained by the above method include a DNA having the base sequence shown in SEQ ID NO: 14.
- cDNA at the 5 'end from the amplified fragment can be obtained [Pnx: Natl. Acad. Sci. USA, 85, 8998 (1988)].
- cDNA of IL-14-stimulated vascular endothelial cells is synthesized by the same method as SCREENJ of the cDNA library, adapters are added to both ends of the cDNA, the nucleotide sequence of this adapter and the amplified fragment PCR is performed with primers based on the nucleotide sequence of the above, and the wide fragment is cloned into a vector in the same manner as described above, so that the cDNA at the end of the amplified fragment obtained from Differential Display is 5, can get.
- the nucleotide sequence of the obtained cDNA can be confirmed by the same method as the screening of the cDNA library. Based on this base sequence, the obtained cDNA and the amplified fragment obtained by Differential Display are joined together to obtain cDNA which is considered to be full length.
- a primer based on the nucleotide sequence of the cDNA was prepared, and the primer was prepared from vascular endothelial cells stimulated with IL-4.
- the DNA of the present invention can also be prepared by chemical synthesis using a DNA synthesizer.
- a DNA synthesizer examples include a DNA synthesizer model 392 (manufactured by Perkin Elma Inc.) using the phosphoramidite method.
- Antisense having a partial nucleotide sequence of the DNA of the present invention by the DNA synthesizer -The oligonucleotide can be chemically synthesized.
- a derivative of the nucleotide can also be used, and examples thereof include a methyl derivative of the nucleotide and a phosphorothioate derivative.
- the recombinant vector of the present invention is constructed by introducing the DNA of the present invention downstream of an appropriate expression vector promoter, and the recombinant vector is introduced into a host cell.
- the transformant of the present invention can be obtained.
- any cell that can express the gene of interest such as bacteria, yeast, animal cells, and insect cells
- the expression vector those which are capable of autonomous replication in the above-mentioned host cell or capable of being integrated into a chromosome, and which contain a promoter at a position where the DNA of the present invention can be transcribed are used.
- a prokaryote such as a bacterium
- the recombinant vector of the present invention is capable of autonomous replication in a prokaryote, and at the same time, is composed of a promoter, a ribosome binding sequence, a DNA of the present invention, and a transcription termination sequence.
- it is configured. It may contain a gene that controls the promoter.
- expression vectors include pKK233-2 (Pharmacia), pSE280 (Invitrogen), pGEMEX-1 (Promega), pQE-8 (QIAGEN), pKYPIO (Special 58-110600), pKYP200 [Agricul tural Biological Chemistry, 48, 669 (1984)], pLSAl [Agric. Biol. Chem., 53, 277 (1989)], pGELl [Pro Natl. Acad. Sc i USA, 82, 4306 (1985)], pBluescript II SK (-) (Stratagene), pGEX (Pharmacia), pET-3 (Novagen) and the like.
- an expression vector a vector in which the distance between the Shine-Dalgarno sequence, which is a ribosome binding sequence, and the initiation codon is adjusted to an appropriate distance (for example, 6 to 18 bases) is used. Preferably.
- Any promoter can be used as long as it can be expressed in a host cell such as Escherichia coli.
- ⁇ promoter one P trp
- lac promoter one p L promoter
- p R promoters such as T7 promoter, promoter, First and the like derived from Escherichia coli or phage, or the like.
- the promoter one obtained by two series P t "(P trp X 2 ), promoter mono-, lacT7 promoter primary, artificially designed and modified promoters like the let I promoter one or the like can be used.
- a transcription termination sequence is not necessarily required for expression of the DNA of the present invention, but it is preferable to arrange a transcription termination sequence immediately below a structural gene.
- host cells include microorganisms belonging to the genera Escherichia, Bacillus, Corynebacterium, Brevibacterium, Pseudomonas, Serratia, etc., for example, Escherichia-colli XL1-Blue MRr ', Escherichia col i DHK Escherichia col ⁇ Door 09, Escherichia col i HB101, Bac i 1 lus subt i 1 is, Bac i 1 lus amylol iquefac ines, Brevibacterium immariophi lum ATCC 14068, Brevibacterium saccharolyt icum ATCC 14066, Corynebacterium g ace ut um um um ut um um um cer um um cerum um um um um germ um um um germ ATum I can give it.
- Any method for introducing a recombinant vector can be used as long as it is a method for introducing DNA into the above host cells.
- the calcium chloride method [Pro Natl. Acad. Sci. USA, 69, 2110 ( 1972)]
- the protoplast method Japanese Patent Application Laid-Open No. 63-2483942
- the electroreaction method and the like.
- YEpl3 ATCC37115
- YEp24 ATCC37051
- YCp50 ATCC37419
- Any promoter can be used as long as it can be expressed in yeast strains.
- promoters for glycolytic genes such as hexose kinase can be used.
- uncle cells include aaccharomyces cerevis ⁇ Schizosaccharomvces pombe Kluvveromyces lact is Trichosporon pul lulatis, Schwann iomvces alluvius and the like.
- any method can be used as long as it is a method for introducing DNA into yeast.
- electroporation Methods. Enzymol., 194, 182 (1990)]
- Sufiplus Natl. Acad. Sci. USA 81, 4889 (1984)
- the lithium acetate method Journal of Bacteriology, 153, 163 (1983)].
- expression vectors include, for example, pAGE107 [JP-A-3-22979, Cytotechnology, 3, 133, (1990)], pAS3-3 (JP-A-2-227075), pCD8 [ Nature, 329, 840, (1987)], pcDNAI / Amp (Invitrogen), pREP4 (Invitrogen), pAGE103 [Journal of Biochemistry, 101, 1307 (1987)] and the like.
- Any promoter can be used as long as it can be expressed in animal cells.
- the enhancer of the IE gene of human CMV may be used together with the promoter.
- Examples of the host cell include Namalwa cell, a human cell, COS cell, a monkey cell, CH0 cell, a Chinese hamster cell, and HBT5637 (JP-A-63-299).
- any method for introducing DNA into animal cells can be used.
- the electroporation method [Cytotechnology, 3, 133 (1990)]
- the calcium phosphate method Japanese Patent Laid-Open No. 2-227075
- the lipofection method [Pro Natl. Acad. Sci. USA, 84, 7413 (1987)] and the like.
- Proteins can be expressed according to the method described in Bio / Technology, 6, 47 (1988) and the like.
- the recombinant vector of the present invention (hereinafter, also referred to as the recombinant gene transfer vector of the present invention) and baculovirus were co-transfected into insect cells to obtain a recombinant virus in the insect cell culture supernatant. Later, insect cells can be further infected with the recombinant virus to express the protein.
- Examples of the gene transfer vector used in the method include pVL1392, pVL1393, pBlueBacIII (all manufactured by Invitrogen) and the like.
- Baculoviruses include, for example, autographa calli fornica nuclear polynedros is virus, a virus that infects insects of the night roth moth family, such as autographa, californica and nuclei. .
- Sf9 and Sf21 which are ovarian cells of Spodoptera frugiperda [Baculovirus Express Ion ectors, A Laboratory Manual, New York (1992)], and High 5 which is an ovarian cell of Trichoplus ia ni (manufactured by Invitrogen) Etc. are used ⁇ t.
- a method for co-introducing the recombinant gene transfer vector of the present invention into insect cells and the above baculovirus to prepare a recombinant virus includes, for example, the calcium phosphate method (Japanese Patent Application Laid-Open No. 2-227075). Acad. Sci. USA, 84. 7413 (1987)], and the like.
- sugar or sugar chain-added protein When expressed by yeast, animal cells or insect cells, a sugar or sugar chain-added protein can be obtained.
- the protein of the present invention can be produced by culturing the transformant of the present invention in a medium, producing and accumulating the protein of the present invention in the culture, and collecting from the culture.
- the method for culturing the transformant of the present invention in a medium can be performed according to a usual method used for culturing a host.
- a culture medium for culturing a transformant obtained by using a prokaryote such as Escherichia coli or a eukaryote such as yeast as a host contains a carbon source, a nitrogen source, inorganic salts, and the like which can be used by the organism. Either a natural medium or a synthetic medium can be used as long as the medium can efficiently culture the cells.
- the carbon source may be any one that can be assimilated by the organism, such as glucose, fructose, sucrose, molasses containing these, carbohydrates such as starch or starch hydrolysate, and organic acids such as acetic acid and propionic acid. Acids, alcohols such as ethanol and propanol, and the like can be used.
- nitrogen source examples include ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate, and other ammonium or inorganic salts of organic acids, and other nitrogen-containing compounds, as well as peptone, meat extract, yeast extract, and corn starch. 1. Casein hydrolyzate, soybean meal and soybean meal hydrolyzate, various fermented cells, digested products thereof, and the like can be used.
- Potassium phosphate, potassium phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, calcium carbonate, etc. are used as inorganic substances. be able to.
- the culture is usually performed under aerobic conditions such as shaking culture or deep aeration stirring culture.
- the cultivation temperature is 15 to 4 (TC is good, the cultivation period is usually 16 to 96 hours.
- the pH is maintained at 3.0 to 9.0.
- the pH is adjusted by using inorganic or organic acids, Alkaline solution, urea, charcoal Perform using calcium acid, ammonia, etc. If necessary, an antibiotic such as ampicillin-tetracycline may be added to the medium during the culture period.
- an Indianer When culturing a microorganism transformed with an expression vector using an inducible promoter as a promoter, an Indianer may be added to the medium as necessary.
- an Indianer When culturing a microorganism transformed with an expression vector using a promoter, isopropyl-1-D-thiogalactopyranoside or the like is used.
- indole atari When culturing a microorganism transformed with an expression vector using a tr ° mouth motor, indole atari is used. Luic acid or the like may be added to the medium.
- RPMI1640 medium As a medium for culturing a transformant obtained using animal cells as a host, RPMI1640 medium, Eagle's MEM medium, or a medium obtained by adding fetal calf serum or the like to such a medium is used.
- Culturing is carried out under conditions such as normal 5% C 0 2 presence.
- the culture temperature is preferably 35 to 37, and the culture time is usually 3 to 7 days.
- antibiotics such as kanamycin and penicillin may be added to the medium during the culture.
- Culture media for transformants obtained using insect cells as a host include TNM-FH medium (Pharmingen), Sf-900II SFM medium (Life's Technologies), ExCel l400 And ExCel 140 (both manufactured by JRH Biosciences).
- the cultivation temperature is preferably 25-30, and the cultivation period is usually 1-4 days. If necessary, an antibiotic such as gentamicin may be added to the medium during the culture period.
- a normal protein isolation and purification method may be used.
- the protein of the present invention when expressed in a lysed state in cells, after the culture is completed, the cells are collected by centrifugation, suspended in an aqueous buffer, and then sonicated with a sonicator, french press, manntone. Cells are disrupted using a Gaulin homogenizer, Dynomill, etc. Obtain a cell-free extract.
- a normal protein isolation and purification method that is, a solvent extraction method, a salting-out method with ammonium sulfate, a desalting method, a precipitation with an organic solvent, Method, getylaminoethyl (DEAE)-Sepharose, DIAION HPA-75 (manufactured by Mitsubishi Kasei Co., Ltd.) using resin such as anion exchange chromatography, S- Sepharose FF (manufactured by Pharmacia) Cation exchange chromatography used, hydrophobic chromatography using resins such as butyl sepharose and phenylsepharose, gel filtration using molecular sieves, affinity chromatography, and chromatofocusing
- a purified sample can be obtained by using a method such as electrophoresis such as isoelectric focusing or isoelectric focusing alone or in combination.
- the cells are similarly recovered, crushed, and recovered from the precipitate fraction obtained by centrifugation in a usual manner. After that, the insoluble form of the protein is solubilized with a protein denaturant. After diluting or dialyzing the solubilized solution to a solution containing no protein denaturing agent or diluting the concentration of the protein denaturing agent so that the protein is not denatured, the protein is restored to a normal three-dimensional structure.
- a purified sample can be obtained by the same isolation and purification method as described above.
- the protein of the present invention or a derivative such as a modified sugar thereof is secreted extracellularly
- the protein or a derivative such as a sugar chain adduct thereof can be recovered in the culture supernatant. That is, a soluble fraction is obtained by treating the culture by a method such as centrifugation as described above, and a purification standard is obtained from the soluble fraction by using the same isolation and purification method as described above. Goods can be obtained.
- the protein of the present invention can also be produced by a chemical synthesis method such as the Fmoc method (fluorenylmethyloxycarbonyl method) and the tBoc method (t-butyloxycarbonyl method).
- a chemical synthesis method such as the Fmoc method (fluorenylmethyloxycarbonyl method) and the tBoc method (t-butyloxycarbonyl method).
- peptide synthesizers manufactured by Advanced ChemTech, Perkin's Elma, Pharmacia, and Protein 'Technology, Synthesizer -Vega (Synthecel-Vega), PerSeptive, Shimadzu, etc.] can be used for chemical synthesis.
- the structural analysis of the purified protein of the present invention is performed by a method generally used in protein chemistry, for example, a method described in Protein Structural Analysis for Gene Cloning (Hisashi Hirano, published by Tokyo Chemical Dojin, 1993). Can be implemented.
- the protein of the present invention releases various mediators having cell killing activity or parasiticidal activity, such as proteins and active oxygen in eosinophil granules, from eosinophils. It can accumulate eosinophils, and it can be used for parasite infections such as filamentous worms, schistosomes, lung flukes, hookworms, ciliates, lung nematodes, jaw and mouth insects, tapeworms, ascoma, etc. It can be used as a therapeutic agent for tumors and the like.
- compositions comprising the protein of the present invention, also there is a force to be administered in protein alone as a therapeutic agent?, Usually with a carrier on one or even more than is allowed the protein pharmacological It is desirable to mix and provide as a pharmaceutical preparation manufactured by any method well known in the pharmaceutical arts.
- an aseptic solution dissolved in water or an aqueous carrier such as an aqueous solution of salt, glycine, glucose, human albumin or the like is used.
- pharmacologically acceptable additives such as buffering agents and tonicity agents for bringing the formulation solution closer to physiological conditions, for example, sodium acetate, sodium chloride, sodium lactate , Potassium chloride, sodium citrate and the like can also be added. It can also be lyophilized for storage and dissolved in a suitable solvent before use.
- a parenteral route such as a subcutaneous, intramuscular, intravenous, or respiratory route is used.
- the therapeutic agent containing the protein of the present invention may be mixed with one or more carriers which are usually pharmacologically acceptable, such that the compound can be administered alone as a therapeutic agent. It is desirable to provide as a pharmaceutical preparation manufactured by any method well known in the pharmaceutical art.
- Corrected form (Rule 91) It is desirable to use the most effective route for treatment.Use oral or parenteral, such as buccal, respiratory, rectal, subcutaneous, intramuscular, and intravenous administration. Can be. Dosage forms include sprays, capsules, tablets, granules, syrups, emulsions, suppositories, injections, ointments, tapes and the like.
- Formulations suitable for oral administration include emulsions, syrups, capsules, tablets, powders, granules and the like.
- liquid preparations such as emulsions and syrups include water, sugars such as sucrose, sorbitol and fructose, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, olive oil and soybean oil, p — It can be manufactured using preservatives such as hydroxybenzoic acid esters, flavors such as bevel flavor and peppermint as additives.
- excipients such as lactose, glucose, sucrose, mannitol, disintegrants such as starch, sodium alginate, lubricants such as magnesium stearate, talc, poly It can be produced using a binder such as vinyl alcohol, hydroxypropylcellulose, and gelatin, a surfactant such as a fatty acid ester, and a plasticizer such as glycerin as additives.
- Formulations suitable for parenteral administration include injections, suppositories, sprays and the like.
- an injection is prepared using a carrier comprising a salt solution, a glucose solution, or a mixture of both.
- Suppositories are prepared using carriers such as cocoa butter, hydrogenated fats or carboxylic acids.
- Sprays are prepared using the compound itself or a carrier which does not irritate the oral and respiratory mucosa of the recipient and which disperses the compound as fine particles to facilitate absorption.
- Specific examples of the carrier include lactose, glycerin and the like.
- Formulations such as aerosols and dry powders are possible depending on the properties of the compound and the carrier used.
- the components exemplified as additives for oral preparations can also be added.
- the dose or frequency of administration varies depending on the desired therapeutic effect, administration method, treatment period, age, body weight, etc., and is usually 10 g / kg to 8 mg / kg per day for an adult.
- a method such as a method for measuring intracellular calcium concentration, a chemotaxis assay, a receptor binding assay, or the like, a cell on which the protein of the present invention specifically acts, or Cell membranes or receptors that specifically bind to the protein of the invention can be detected or obtained.
- the test sample includes, for example, cells or tissues on which the protein of the present invention specifically acts, or cell membranes or receptors specifically binding to the protein of the present invention.
- Cells on which the protein of the present invention specifically acts include, for example, leukocytes.
- white blood cells include B cells, T cells, lymphocytes such as large granular lymphocytes, mononuclear phagocytes, phagocytic cells such as neutrophils and eosinophils, basophils, mast cells, platelets, etc.
- Eosinophils which can be used as auxiliary cells, are preferably used.
- the cells may be in any form such as a single cell, a cell clump, or a tissue.
- the cell membrane or receptor that specifically binds to the protein of the present invention include cell membranes prepared from the above cells, or receptors isolated and purified from the cells.
- the calcium concentration in the cells can be reduced. Detect changes. It can be determined that the protein of the present invention acts on cells whose intracellular calcium concentration increases transiently.
- test sample e.g., eosinophils
- protein solution of the present invention into the lower chamber, and let it stand for an appropriate time.
- labeling the protein of the present invention with a radioactive isotope and the like Using a method such as to be added to 125 1 with Bo 1 ton-Hunter reagent Tyr residue of the protein of the present invention, labeling the protein of the present invention with a radioactive isotope and the like.
- the labeled protein and the membrane fraction prepared from the cells are mixed and reacted at 4 ° C to 37 for 20 minutes to 24 hours.
- the mixture is filtered through a glass filter or the like, washed, and the amount of radioactivity in the membrane fraction isolated on the filter is measured to determine the total amount of binding.
- a cell showing specific binding between the protein of the present invention and the receptor in this assay system is determined to be a cell having a receptor that specifically binds to the protein of the present invention.
- test compound examples include low molecular weight compounds, peptides, proteins, and antibodies.
- increase in calcium concentration is measured by adding a test compound, and the protein of the present invention is measured.
- a substance that causes a smaller increase in calcium concentration than when only a buffer and a buffer solution are added can be selected as an antagonist.
- the amount of specific binding to the receptor that specifically binds to the protein of the present invention is measured, and a substance whose specific binding amount is reduced as compared with the case where no protein is added is selected as the substance that binds to the receptor.
- a test compound alone is added in place of the protein of the present invention in this system, those exhibiting the same action as the protein of the present invention can be determined as agonists, and those exhibiting the antagonistic action can be determined as antagonists.
- the agonist of the present invention has the ability to activate eosinophils like the protein of the present invention, it can be used as a therapeutic agent for parasitic infections or malignant tumors.
- the antagonist of the present invention antagonizes the protein of the present invention and suppresses infiltration of eosinophils activated by the protein of the present invention, whereby diseases involving infiltration of eosinophils, such as asthma, Remedies for allergic conjunctivitis, allergic rhinitis, atopic dermatitis, allergic inflammatory diseases such as allergic bronchopulmonary aspergillosis, eosinophilic pneumonia or idiopathic eosinophilia (hypereos inophilic syndrome) It can be used as When the antagonist of the present invention is a chemokine protein antagonist, it can be used as a therapeutic drug for autoimmune deficiency diseases such as autoimmune hemolytic anemia, primary biliary cirrhosis, and progressive erythematodes.
- a medicament containing the agonist or antagonist of the present invention is prepared or administered using the same method as the medicament containing the protein of the present invention except that the agonist or antagonist of the present invention is used
- the antibody of the present invention may be any of polyclonal antibodies, monoclonal antibodies, etc., as long as they can specifically bind to the protein of the present invention.
- Polyclonal antibodies can be prepared by separating and purifying serum obtained from animals immunized with the antigen.
- Monoclonal antibodies are prepared by fusing antibody-producing cells obtained from animals immunized with the antigen with myeloma cells to produce hybridomas, culturing the hybridomas, and administering the animals to animals to ascites cancer. And said It can be prepared by separating and purifying a culture solution or ascites.
- the antigen is expressed by isolating and purifying the protein of the present invention from various human cultured cells or introducing the recombinant vector of the present invention into a non-human host such as Escherichia coli, yeast, animal cells, insect cells, etc., and expressing the protein. It can be prepared by separating and purifying the protein of the present invention thus obtained.
- the antigen can also be prepared by synthesizing a polypeptide having a partial sequence of the protein of the present invention using an amino acid synthesizer.
- the antigen may be directly administered subcutaneously, intravenously or intraperitoneally to a non-human mammal such as a rabbit, a goat or a rat, mouse or hamster of 3 to 20 weeks old.
- a non-human mammal such as a rabbit, a goat or a rat, mouse or hamster of 3 to 20 weeks old.
- Antigens can be administered by binding antigens to carrier proteins with high antigenicity, such as keyhole limpet mosquito, keyhole limpet hemocyanin, bovine serum albumin, bovine thyroglobulin, etc., or Complete Freund's Adjuvant. ), Aluminum hydroxide gel, pertussis vaccine, etc., preferably with an appropriate adjuvant.
- the administration of the antigen is performed 3 to 10 times every 1 to 2 weeks after the first administration.
- Blood is collected from the fundus venous plexus 3 to 7 days after each administration, and an enzyme immunoassay is performed to determine whether the serum reacts with the antigen used for immunization (Antibodies-A Laboratory Manual, Cold Spring Harbor Laboratory, 1988) Investigate by measuring the antibody titer according to the above.
- a non-human mammal whose serum shows a sufficient antibody titer against the antigen used for immunization is used as a source of serum or antibody-producing cells.
- a polyclonal antibody can be prepared by separating and purifying the serum.
- a monoclonal antibody is prepared by fusing the antibody-producing cells with myeloma cells derived from a non-human mammal to produce a hybridoma, and administering the hybridoma to a cultivated animal to cause ascites carcinoma of the animal. It can be prepared by separating and purifying the culture solution or ascites.
- Antibody producing cells include spleen cells, lymph nodes, antibody producing cells in peripheral blood, especially spleen Cells are preferably used.
- Myeloma cells include 8-azaguanine-resistant mouse (derived from BALB / c) myeloma cell line P3-X63Ag8-Ul (P3-U1) [Current Topics in Microbiology and Immunology, 18, 1-7 (1978 )], P3-NSl / l-Ag41 (NS-1) strain [European J. Immunology, 6, 511-519 (1976)], SP2 / 0-Agl4 (SP-2) strain [Nature, 276, 269- 270 (1978)], P3-X63-Ag8653 (653) strain [J. Immunology, 123, 1548-1550 (1979)], P3-X63-Ag8 (X63) strain [Nature, 256, 495-497 (1975)] And the like. Cell lines derived from mice are preferably used.
- Hybridoma cells can be prepared by the following method.
- the antibody-producing cells and myeloma cells are mixed, suspended in HAT medium [medium containing hypoxanthine, thymidine and aminopterin in normal medium], and cultured for 7 to 14 days. After cultivation, a portion of the culture supernatant is removed, and those that react with the antigen but do not react with the protein containing no antigen are selected by enzyme immunoassay or the like. Then, the cells are cloned by the limiting dilution method, and those having a stable and high antibody titer determined by the enzyme immunoassay are selected as monoclonal antibody-producing hybridoma cells.
- HAT medium medium containing hypoxanthine, thymidine and aminopterin in normal medium
- the monoclonal antibody is obtained by separating and purifying a culture solution obtained by culturing the hybridoma cells, or ascites obtained by intraperitoneally administering the hybridoma cells to the animal and causing the animal to develop ascites cancer. Can be prepared.
- Methods for separating and purifying polyclonal or monoclonal antibodies include centrifugation, ammonium sulfate precipitation, caprylic acid precipitation, or DEAE-Sepharose column, anion exchange column, protein A or G-column, or gel filtration column. Chromatography, etc., used alone or in combination.
- the antibody of the present invention specifically reacts with the protein of the present invention, it inhibits the infiltration of eosinophils activated by the protein of the present invention, and thus is involved in diseases involving infiltration of eosinophils. For example, allergic inflammatory disease, eosinophilic pneumonia or idiopathic eosinophilia It can be used as a remedy for diseases and the like.
- the antibody of the present invention specifically reacts with a chemokine protein, it can be used as a therapeutic drug for an autoimmune deficiency disease.
- the medicament containing the antibody of the present invention is prepared or administered using the same method as the medicament containing the protein of the present invention except that the antibody of the present invention is used instead of the protein of the present invention.
- the protein of the present invention can be immunologically detected or quantified by using the antibody of the present invention.
- Examples of the method for immunological detection include ELISA using a microtiter plate, fluorescent antibody, western blotting, and immunohistological staining.
- This as a method for immunologically quantifying the Sanditsuchi ELISA method Epitopu were used two different monoclonal antibodies of the antibodies that react with the protein of the present invention in the liquid phase, labeled with a radioisotope such as 125 1
- the radioimmunoassay method using the protein of the present invention and an antibody recognizing the protein of the present invention can be exemplified. It can also be used for immunohistological staining using pathological tissue sections.
- the protein of the present invention present in cells or tissues of healthy subjects and subjects is immunologically detected or quantified, and the amount is compared between healthy subjects and subjects.
- the antibody of the present invention can be used as a diagnostic agent for allergic inflammation, eosinophilic pneumonia, idiopathic eosinophilia or autoimmune disease.
- the sense DNA and antisense DNA of the DNA of the present invention can be used as they are, or as oligonucleotides each containing a part of their base sequence, as northern blot hybridization, southern blot hybridization, in situ hybridization. It can be used as a probe such as a probe or a primer for PCR, RT-PCR and the like.
- Oligonucleotides having a partial base sequence of the base sequence of the present invention include DNAs of the present invention, for example, DNA having a base sequence represented by SEQ ID NO: 12; Oligonucleotides having a base sequence of 10 to 50 residues can be mentioned.
- Oligonucleotides include DNA, RNA or derivatives thereof, for example, the methyl-phosphorothioate form.
- the DNA of the present invention can be obtained by using a Northern blot hybridization method, an RT-PCR method, or the like by using the DNA containing the DNA of the sense DNA or antisense DNA or a part of the base sequence of the DNA.
- the mRNA encoding the protein of the present invention can be detected and quantified.
- RNA isolated from tissues or cells into cDNA using oligo (dT) primers and reverse transcriptase, and then combining a set of oligonucleotides corresponding to the mRNA to be detected with the primers.
- dT oligo primers and reverse transcriptase
- Oligonucleotide primers include a sense primer corresponding to the base sequence at the 5 'end and an antisense primer corresponding to the base sequence at the 3' end in the partial base sequence of the mRNA to be detected.
- the base corresponding to peracyl in mRNA is thymidine in oligo nucleotide primers.
- the number of bases is preferably 5 to 100 bases, particularly preferably 10 to 50 bases.o
- the nucleotide sequence portion to be amplified using the oligo nucleotide primer may be any nucleotide sequence region of mRNA, but the nucleotide sequence length is 50 bp to 2 kbp, and the repeat sequence or GC (guanine cytosine) nucleotide A base sequence region that does not contain a sequence rich in oxygen is preferred.
- the antisense DNA of the present invention [Chemistry, 681 (1991), Biotechnology 9, 358 (1992)] is used to suppress the transcription of DNA or the translation of mRNA, thereby achieving autoimmunity. It can also be used to treat diseases. Suppression of chemokine protein production using the antisense DNA technology is based on a partial nucleotide sequence of DNA encoding the protein of the present invention, preferably a nucleotide sequence of 10 to 50 nucleotides in the translation initiation region. This can be done by designing and preparing an oligonucleotide in such a manner and then administering it to a living body.
- the nucleotide sequence of the synthetic oligonucleotide is a nucleotide sequence that matches a part of the nucleotide sequence of the antisense strand of the DNA of the present invention, or is modified within a range that does not lose the activity of suppressing the expression of the activity of the protein. Can be used.
- the protein of the present invention expressed in cells or tissues of healthy subjects and subjects is coded.
- MRNA is detected or quantified by the Northern hybridization method, PCR method, etc., and the amount is compared between healthy subjects and subjects to determine whether the expression level is increased. Diagnosis of sexual inflammation, eosinophilic pneumonia, idiopathic eosinophilia, autoimmune disease, malignancy or parasitic infection can be diagnosed.
- the sense DNA of the DNA of the present invention can be used as a diagnostic agent for allergic inflammation, eosinophilic pneumonia, idiopathic eosinophilia, autoimmune disease, malignant tumor or parasitic infection.
- the oligonucleotide of the present invention containing a part of the nucleotide sequence of the sense DNA or antisense DNA of the DNA is also useful as a reagent for gene research.
- the antisense DNA of the DNA of the present invention and the oligonucleotide containing a part of the nucleotide sequence thereof can suppress the transcription or translation of the mRNA of the present invention. Therefore, by suppressing the infiltration of eosinophils activated by the protein of the present invention, diseases associated with eosinophil infiltration, such as allergic inflammatory disease, eosinophilic pneumonia or It can be used as a treatment for idiopathic eosinophilia and autoimmune diseases.
- the antisense DNA of DNA of the present invention and a drug containing an oligonucleotide containing a part of the nucleotide sequence thereof are replaced with the antisense DNA of DNA of the present invention and a part of the nucleotide sequence in place of the protein of the present invention.
- the preparation or administration is carried out using the same method as for the drug containing the protein of the present invention except that an oligonucleotide containing is used.
- the sense DNA or antisense DNA of the DNA of the present invention or an oligonucleotide containing a part of these nucleotide sequences may be incorporated as a single strand or a double strand into a virus vector such as a retrovirus or adenovirus, or other vectors. It can be used for gene therapy as a vector for gene therapy.
- FIG. 1 is a diagram showing the structure of plasmid pHVC002.
- SVpA Simian virus 40 (SV40) early gene poly
- a additional signal SV3 'sp 3' splicing signal of the early gene of SV40 lacZ: / 9 galactosidase gene of Escherichia coli
- T7 T7 promoter recognized by T7 phage RNA polymerase.
- Con5 'sp Consensus 5' splicing signal.
- HVC002 HVC002 c D N A
- T3 T3 promoter recognized by R3 phage RNA polymerase
- Plac a promoter of the lactose gene of Escherichia coli
- Pcmv A promoter for the immediate early gene of cytomegalovirus (cytomegalovi rus)
- ColEl ori origin of replication of Col El factor in E. coli
- TKpA Nan noyana of herpes s im l ex vi rus
- Neomycin Neomycin, kanamycin resistance gene
- SV40 ori SV40 replication starting point
- FIG. 2 is a diagram showing a comparison of the amino acid sequences of the HVC002 protein and other human CC chemokines, excluding the signal peptide, of the mature protein.
- CC chemokines compared to HVC002 are MIP-1a, MIP-1 ⁇ , RANTES, MCP-2, MCP-3, MCP-4, eotaxin and eotaxin-2.
- the same amino acid as the HVC002 protein is shown in inverted black and white.
- the homology in amino acid sequence with HVC002 protein is shown in%.
- FIG. 3 is a graph showing the results of dust blotting performed on thioredoxin-HVC002 fusion protein expressed in E. coli using mouse antiserum and monoclonal antibody KM1885.
- KM1885 Western blotting using monoclonal antibody KM1885
- Escherichia coli contaminating protein (supersonic crushed supernatant of Escherichia coli AD494 (DE3) pLysS containing pET32a (+)) 5 g
- FIG. 4 shows the results of 15% SDS-PAGE of HVC002 protein purified after expression in insect cells. 0.5 ng of purified HVC002 protein was electrophoresed on the right and a molecular weight marker was electrophoresed on the left, followed by silver staining. Arrows indicate the position of HVC002 protein.
- FIG. 5 shows the results of calcium mobilization of HVC002 protein on human peripheral eosinophils and HL-60 (clonel5) differentiated into eosinophil-like cells by treatment with 0.5 mM butyric acid.
- A is the result of using human peripheral eosinophils
- B is the result of using HL-60 (clonel5)
- the horizontal axis is the time
- the vertical axis is the specific fluorescence intensity (fluorescence intensity when excited at 340 nm, excitation at 380 nm) (Intensity of fluorescence when performed).
- the specific fluorescence intensity is proportional to the intracellular calcium concentration.
- the arrows indicate the time points at which the HVC002 protein or buffer was added, respectively.
- HUVEC umbilical vein vascular endothelial cells, manufactured by Kurabo Industries
- HUVEC is composed of heparin sodium, Endothelial cell growth supplement (Becton-Dickinson), 10% fetal serum (Bio Tech. International Co., Ltd.) , With 1% penicillin (5,000units Zml) 'scan streptomycin (5MgZml) solution (Gibco BRL) and 0.15% NaHC0 3 F-12K medium containing (Sigma) (manufactured by Dainippon Pharmaceutical Co., Ltd.) The cells were cultured under the condition of 5% CO 2 , 37.
- HUVEC stimulated with IL-4 5 X10 100 units of Zml human IL-4 (Zymodin) was added to a medium containing 6 cells, and after culturing for 17 hours, cells (hereinafter referred to as HUVEC stimulated with IL-4) were collected. did.
- LOmgZml human TNF- ⁇ manufactured by Zymodin was added to a medium containing 5 X 10 6 cells, and the cells were cultured for 17 hours. After culturing for 17 hours without adding anything to a medium containing 5 ⁇ 10 6 cells, the cells (hereinafter referred to as unstimulated HUVECs) were collected.
- RNA was obtained by the AGPC method [Experimental Medicine_ £, 1937, (1991)]. That is, 5 ml of D solution (4 M guanidinium thiosinate, 25 mM sodium citrate, 0.5% n-lauryl sarcosine, 0.1 M 2-mercaptoethanol) was added to the recovered cells, and the cells were lysed. After that, 0.7 ml of 2 M sodium acetate (pH 4.0) was added.
- D solution 4 M guanidinium thiosinate, 25 mM sodium citrate, 0.5% n-lauryl sarcosine, 0.1 M 2-mercaptoethanol
- RNA was precipitated by centrifugation at 000 ⁇ g for 10 minutes. The supernatant was removed, and the precipitate was washed with 75% ethanol and dried under reduced pressure. The precipitate was dissolved in 3001 of distilled water, 3001 of 4M LiCl was added, mixed well, left on ice for 1 hour, and centrifuged at 15,000Xg for 10 minutes at 4 to precipitate RNA. . The supernatant was removed, and the precipitate was washed with 75% ethanol, dried, and dissolved in distilled water 221. 36 g of HUVEC stimulated with IL-4, 64 g of HUVEC stimulated with TNF- ", and total RNA from unstimulated HUVEC were obtained. (2) Fluorescent differential display using HUVEC total RNA
- HUVE stimulated with IL-4 TNF-For total RNA of HUVEC stimulated and unstimulated HUVEC add distilled water to each 2.5 RN of each RN to 2.5 lbs.
- Anchor-primer-FAH the nucleotide sequence is shown in SEQ ID NO: 4; 50 M, manufactured by Saddy I
- FITC olescein isothiocyanate
- reaction solution 5 X reverse transcriptase reaction buffer [250mM Tris-HCl (pH8.3) , 275mM KCU 15m M gCl 2] 4 1, lOOmM Jichiosurei Torr (DTT) 2 1, 10mM dNTP (dATP, dGTP, ( ⁇ and dCTP) 1 ⁇ 1, distilled water 1 mu 1, reverse transcriptase SUPERSCRIPT ⁇ II RNAse
- H-Reverse Transcriptase (Life 'Technologies, Inc.) 1 1 (200 units), mix, allow to stand at room temperature for 10 minutes, react at 42 with 50 minutes to synthesize cDNA, The reaction was stopped by heating for minutes.
- a TE buffer (10 mM Tris-HCl (pH 8.0), lmM ethylenediaminetetraacetate sodium (EDTA) ( ⁇ . ⁇ )] 401 was added to the reaction solution to prepare a cDNA solution.
- the DNA was reacted at 72 ° C. for 5 minutes to amplify the DNA fragment.
- a solution for electrophoresis sample (95% formamide, 0.1% xylenesanol, 0.1% bromphenol) to reaction solution 41, heat at 95C for 2 minutes, and immediately cool with ice. Electrophoresis was performed on a 6% acrylamide gel. 89 mM Tris (hydroxymethyl) aminoaminomethane, 89 mM boric acid as electrophoresis buffer , 2 mM EDTA was used.
- MC Bioproducts stained with ethidium mouth, and amplified DNA fragments were cut out.
- the DNA fragment was heated at 65 for 15 minutes to melt the agarose, extracted with phenol-chloroform, extracted with chloroform-isoamyl alcohol, precipitated with ethanol, and dissolved in TE buffer 101.
- DNA fragment solution 1 1 and PCR fragment cloning vector pT7Blue T-Vector
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97946126A EP0949271A1 (en) | 1996-12-05 | 1997-12-05 | Novel dna, novel protein, and novel antibody |
AU51376/98A AU5137698A (en) | 1996-12-05 | 1997-12-05 | Novel dna, novel protein, and novel antibody |
CA002274309A CA2274309A1 (en) | 1996-12-05 | 1997-12-05 | Novel dna, novel protein, and novel antibody |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8/325762 | 1996-12-05 | ||
JP32576296 | 1996-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998024817A1 true WO1998024817A1 (fr) | 1998-06-11 |
Family
ID=18180346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/004470 WO1998024817A1 (fr) | 1996-12-05 | 1997-12-05 | Nouvel adn, nouvelle proteine et nouvel anticorps |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0949271A1 (ja) |
AU (1) | AU5137698A (ja) |
CA (1) | CA2274309A1 (ja) |
WO (1) | WO1998024817A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002033069A1 (fr) * | 2000-10-13 | 2002-04-25 | Genox Research, Inc. | Procede de diagnostic d'une maladie allergique |
JP2005525089A (ja) * | 2001-12-17 | 2005-08-25 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | ケモカイン・アンタゴニストとして作用するケモカイン突然変異体 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006083390A2 (en) * | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
WO2012178188A2 (en) | 2011-06-23 | 2012-12-27 | Children's Hospital Medical Center | Molecular diagnostic panel of eosinophilic gastrointestinal disorders |
WO2017123401A1 (en) | 2016-01-13 | 2017-07-20 | Children's Hospital Medical Center | Compositions and methods for treating allergic inflammatory conditions |
US11859250B1 (en) | 2018-02-23 | 2024-01-02 | Children's Hospital Medical Center | Methods for treating eosinophilic esophagitis |
-
1997
- 1997-12-05 CA CA002274309A patent/CA2274309A1/en not_active Abandoned
- 1997-12-05 EP EP97946126A patent/EP0949271A1/en not_active Withdrawn
- 1997-12-05 WO PCT/JP1997/004470 patent/WO1998024817A1/ja not_active Application Discontinuation
- 1997-12-05 AU AU51376/98A patent/AU5137698A/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
BIOCHEM. BIOPHYS. RES. COMMUN., (October 1996), Vol. 227, No. 1, GAFFNEY A.B. et al., "Eotaxin Stimulates Eosinophil Adhesion to Human Lung Microvascular Endothelial Cells", p. 35-40. * |
FEBS LETTERS, (1994), Vol. 351, No. 2, ITO T. et al., "Fluorescent Differential Display ...", p. 231-236. * |
J. ALLERGY CLIN. IMMUNOL., (January 1996), Vol. 97, No. 1, Pt. 3, ROTHENBERG M.E. et al., "Eotaxin is an Eosinophil Chemokine Produced by Endothelial and Epithelial Cells and During IL-4 Tumor Suppression", p. 273. * |
PROC. NATL. ACAD. SCI. U.S.A., (1995), Vol. 92, No. 19, ROTHENBERG M.E. et al., "Murine Eotaxin: An Eosinophil Chemoattractant Inducible in Endothelial Cells and in Interleukin 4-Induced Tumor Suppression", p. 8960-8964. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002033069A1 (fr) * | 2000-10-13 | 2002-04-25 | Genox Research, Inc. | Procede de diagnostic d'une maladie allergique |
JP2005525089A (ja) * | 2001-12-17 | 2005-08-25 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | ケモカイン・アンタゴニストとして作用するケモカイン突然変異体 |
Also Published As
Publication number | Publication date |
---|---|
CA2274309A1 (en) | 1998-06-11 |
EP0949271A1 (en) | 1999-10-13 |
AU5137698A (en) | 1998-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4085114B2 (ja) | 炎症アデノイドで発現する新規なケモカイン及びその製造と使用 | |
US5426181A (en) | DNA encoding cytokine-induced protein, TSG-14 | |
EP0567575B1 (en) | Cytokine-induced protein, tsg-6, dna coding therefor and uses thereof | |
US6077948A (en) | Mediators of chronic allograft rejection (AIF-1) and DNA encoding them | |
US5602008A (en) | DNA encoding a liver expressed chemokine | |
US5945506A (en) | Chemokine expressed in fetal spleen and its production | |
US6051697A (en) | Chemokine expressed in eosinophils | |
WO2006073052A1 (ja) | 新規血管新生抑制因子 | |
US6210905B1 (en) | Tumor necrosis factor stimulated gene 6 (TSG-6) binding molecules | |
WO1996016979A9 (en) | Expressed chemokines, their production and uses | |
US7932363B2 (en) | Antibody that binds human eosinophil-derived basic protein | |
JP2002537796A (ja) | ヒトグリコシル化酵素 | |
JP2000502903A (ja) | インターフェロンγ誘導因子―2をコードする核酸 | |
WO1998024817A1 (fr) | Nouvel adn, nouvelle proteine et nouvel anticorps | |
JP2004516012A (ja) | 新規シグレック類およびそれらの用途 | |
US5840544A (en) | DNA encoding rantes homolog from prostate | |
JPH10512154A (ja) | 膵臓で発現する新規なケモカイン | |
JPH11243960A (ja) | ヒトcc型ケモカインエオタキシン3 | |
WO1998017800A1 (fr) | Larc, nouvelle chimiokine cc humaine | |
US7011941B1 (en) | Human eosinophil-derived basic protein | |
EP1329511A1 (en) | Polypeptide having phospholipase a2 actiivty | |
US20020164704A1 (en) | Novel human monocyte chemotactic proprotein | |
WO2001019864A1 (fr) | Polynucleotides codant pour des nouvelles proteines humaines du recepteur de l'angiotensine ii-1, leur procede de preparation et leur utilisation | |
JP2001500019A (ja) | 顆粒球走化性タンパク質2変異体 | |
WO1998026071A1 (fr) | Chemokine cc humaine elc |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR CA CN CZ HU IL JP KR MX NO NZ PL RO SG SI SK UA US VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09154066 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2274309 Country of ref document: CA Ref country code: CA Ref document number: 2274309 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997946126 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997946126 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997946126 Country of ref document: EP |